MedTrace Logo

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

NCT00659126 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-09-07

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well magnetic resonance imaging (MRI) using contrast imaging agent ferumoxytol works in comparison to standard imaging agent gadolinium in measuring tumors in patients undergoing treatment for brain tumors or other tumors that have spread to the brain. Diagnostic procedures, such as MRI, may help find and diagnose disease and find out how far the disease has spread. MRI scans use radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. The contrast imaging agent ferumoxytol consists of small iron particles taken by the blood stream to the brain and to the area of the tumor. It is highly visible on the MRI, and may help visualize the blood flow going through the tumor better than gadolinium can. Using a more sensitive and faster 7 Tesla (7T) magnet MRI in conjunction with a contrast imaging agent may provide a better way to measure tumors than the 3 Tesla (3T) magnet MRI in patients with brain tumors.

Conditions

  • Metastatic Malignant Neoplasm in the Brain
  • Primary Brain Neoplasm

Interventions

PROCEDURE

3 Tesla Magnetic Resonance Imaging

Undergo 3T MRI

PROCEDURE

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Undergo DCE MRI

PROCEDURE

Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging

Undergo DSC MRI

DRUG

Ferumoxytol

Given IV

DRUG

Gadolinium

Given IV

PROCEDURE

High Field Strength Magnetic Resonance Imaging

Undergo 7T MRI

PROCEDURE

Susceptibility Weighted Imaging

Undergo SWI

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Oregon Health and Science University

    collaborator OTHER

  • OHSU Knight Cancer Institute

    lead OTHER

Principal Investigators

  • Edward Neuwelt · OHSU Knight Cancer Institute

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-16
Primary Completion
2019-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00659126 on ClinicalTrials.gov